Veracyte is trading 4.01% down at $46.59, with no clear company-specific catalyst identified for September 25, 2026. - Its press-release page shows no new announcement since the September 1 acquisition update; recent coverage also identifies no dated catalyst for the preceding surge. - Volume reached 2.88 million shares, versus a 1.36 million three-month average. - Major indexes are higher, so broader market weakness does not explain the decline.